Twist Bioscience CORP Form 4 insider transactions

Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold 806 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 2,422 shares of common stock on January 23, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Adam Laponis, CFO of Twist Bioscience, sold 5,886 shares of common stock on January 10, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Director Robert Chess of Twist Bioscience Corp. sold 5,000 shares of common stock at $50 per share on January 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

A Twist Bioscience executive sold 144 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Twist Bioscience's President and COO, Patrick John Finn, sold 229 shares of common stock to cover tax obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 160 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily M. Leproust sold 546 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience director Robert Chess exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 316 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 282 shares of common stock on December 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO of Twist Bioscience, Emily Leproust, sold 1,654 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Dennis Cho, a Twist Bioscience executive, sold 133 shares of common stock on December 16, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

A Twist Bioscience executive sold shares to cover tax obligations related to the vesting of restricted stock units.

A Twist Bioscience executive sold shares to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily Leproust sold 2,216 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Twist Bioscience executive sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Twist Bioscience CEO Emily Leproust reported the acquisition of 95,350 shares of common stock and various transactions related to employee stock options.

Twist Bioscience's President and COO, Patrick John Finn, was granted 53,634 restricted stock units on December 4, 2024.

Twist Bioscience's Chief Financial Officer, Adam Laponis, acquired 26,745 restricted stock units on December 4, 2024.

Paula Green, SVP of Human Resources at Twist Bioscience, acquired 20,428 shares of common stock through the vesting of a restricted stock unit award.

Dennis Cho, a Senior Vice President at Twist Bioscience, acquired 22,824 shares of common stock through the vesting of restricted stock units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, received 8,438 restricted stock units (RSUs) on December 4, 2024.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 789 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Twist Bioscience executive sold 1,811 shares to cover tax obligations related to vesting performance stock units.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 4,160 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience CEO Emily M. Leproust sold 14,334 shares to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 1,448 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 5,519 shares of common stock to cover tax obligations related to vesting Performance Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 6,239 shares of common stock to cover tax obligations related to vesting Performance Stock Units.